We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Repp86: a new prognostic marker in mantle cell lymphoma.
- Authors
Schrader, Carsten; Janssen, Dirk; Meusers, Peter; Brittinger, Günter; Siebmann, Jens U.; Parwaresch, Reza; Tiemann, Markus
- Abstract
Objectives: Proliferation indices are important prognostic factors for the clinical outcome of patients with mantle cell lymphoma (MCL). We investigated whether the expression of repp86 (restrictedly expressed proliferation-associated protein 86 kDa), a new proliferation specific marker expressed in the cell cycle phases G2, S and M, but not in G1, correlates with the clinical course in patients with MCL. Patients and Methods: Biopsy specimens from 94 untreated patients enrolled in two multicenter trials were investigated immunohistochemically with monoclonal antibodies against CD20, CD5, CD3, CD23, cyclin D1, and repp86 (Ki-S2). Results: Patients with 0–1% repp86 expression had a median overall survival time of 71.0 months, compared with 38.2 months for patients with 1–5% positive cells and 25.4 months for patients with 5–10% positive tumor cells. Patients with repp86 expression of more than 10% showed the shortest survival (median: 15.0 months). Kaplan–Meier analysis revealed a significant difference in the overall survival time between patients with very high (>10%) and very low (0–1%) repp86 expression ( P < 0.0001) in the tumor cells. The multivariate analysis revealed repp86 expression to be superior to other clinical characteristics as a prognostic factor ( P = 0.0016). Conclusion: Based on these findings, repp86 expression is a new important prognostic factor in MCL.
- Subjects
LYMPHOMAS; TUMOR markers; BIOMARKERS; PROGNOSIS; PROTEINS; CELL cycle
- Publication
European Journal of Haematology, 2005, Vol 75, Issue 6, p498
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/j.1600-0609.2005.00540.x